创新药板块多重利好叠加，关注恒生创新药ETF（159316）和创新药ETF易方达（516080）等产品配置价值

Core Insights - The recent strong capital inflow into the innovative drug sector indicates a growing market interest, with over 8 billion yuan net inflow into related ETFs since November [1] - The upcoming release of the first "Commercial Insurance Innovative Drug Directory" in early December is expected to open significant payment channels for innovative drugs [1] - China's innovative drug "going global" trend is accelerating, with the total License-out amount exceeding 100 billion USD from January to October 2025, reflecting a year-on-year growth rate of over 190% [1] Market Trends - The proportion of China's projects in global innovative drug BD transactions has increased from 3% in 2019 to 13% in 2024, with the monetary share rising from 1% to 28%, showcasing the strong global competitiveness of Chinese innovative drug companies [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index is the first "pure" innovative drug index with 100% purity, accurately gathering leading companies in the Hong Kong innovative drug sector [1] - The CSI Innovative Drug Industry Index focuses on A-share innovative drug companies, consisting of no more than 50 leading firms engaged in innovative drug research and development, which are expected to benefit from favorable policies and industry trends [1] Investment Tools - The Hang Seng Innovative Drug ETF (159316) and the E Fund Innovative Drug ETF (516080) track the aforementioned indices, providing investors with convenient tools to invest in leading innovative drug companies [1]